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The SPREAD Programme investigated prospectively the time
trend from September 2002 through December 2005 of trans-
mitted drug resistance (TDR) among 2793 patients in 20
European countries and in Israel with newly diagnosed hu-
man immunodeficiency virus type 1 (HIV-1) infection. The
overall prevalence of TDR was 8.4% (225 of 2687 patients;
95% confidence interval [CI], 7.4%–9.5%), the prevalence of
nucleoside reverse-transcriptase inhibitor (NRTI) resistance
was 4.7% (125 of 2687 patients; 95% CI, 3.9%–5.5%), the
prevalence of nonucleoside reverse-transcriptase inhibitor
(NNRTI) resistance was 2.3% (62 of 2687 patients; 95% CI,
1.8%–2.9%), and the prevalence of protease inhibitor (PI)
resistance was 2.9% (79 of 2687 patients; 95% CI, 2.4%–
3.6%). There was no time trend in the overall TDR or in
NRTI resistance, but there was a statistically significant de-
crease in PI resistance ( ) and in NNRTI resistanceP p .04
after an initial increase ( ). We found that TDR ap-P p .02
pears to be stabilizing in Europe, consistent with recent re-
ports of decreasing drug resistance and improved viral sup-
pression in patients treated for HIV-1 infection.
Despite successful treatment of human immunodeficiency virus
type 1 (HIV-1) infection in Europe [1], there is still a limited
group of individuals with treatment failure who are potentially
at risk of spreading drug-resistant HIV-1. The objectives of the
SPREAD Programme are to determine the prevalence of trans-
mitted drug resistance (TDR) within the participating Euro-
pean countries, to study temporal trends in resistance, and to
investigate possible predictors for TDR [2].
Patients and methods. The SPREAD Programme recruited
patients in whom HIV-1 infection was newly diagnosed from
September 2002 through December 2005 in 20 European coun-
tries (Austria, Belgium, Cyprus, Czech Republic, Germany,
Denmark, Spain, Finland, Greece, Ireland, Italy, Luxembourg,
the Netherlands, Norway, Poland, Portugal, Sweden, Slovenia,
Slovakia, and Serbia) and Israel. To obtain representative sam-
ples from every country, the investigators selected individuals
according to the national distribution of transmission risk
groups and the geographical distribution of patients with new
diagnoses of HIV-1 infection. For more details on the sampling
strategy, see the previous report of the SPREAD Programme
[2]. Epidemiological, clinical, and behavioral data were col-
lected using a standardized questionnaire. A thorough data ver-
ification process preceded the analysis of the data.
The first available measurements of viral load and CD4 cell
counts were collected. A blood sample was taken for genotypic
resistance testing within 6 months after diagnosis. Population-
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based nucleotide sequencing of the reverse-transcriptase (RT)
and protease (PR) genes of the virus was performed at local
laboratories by means of commercially available kits or in-
house methods. The GenBank accession numbers for the se-
quences used in this analysis are listed after the text. All coun-
tries took part in a blinded quality control program to verify
the quality of the genotypic data generated. TDR was defined
according to the recently published list of mutations for sur-
veillance of TDR as recommended by the World Health Or-
ganization [3].
Either the duration of infection in patients with a new di-
agnosis was unknown ( patients with only first con-n p 1878
firmed positive antibody test result date) or seroconversion was
documented ( ). For patients with laboratory evidencen p 809
for acute seroconversion, the date of the first positive reactive
laboratory test result before complete seroconversion (n p
) was used as the estimated date of infection. For other382
documented seroconverters ( ), the date of infectionn p 427
was estimated as the midpoint between the date of the last
documented negative HIV-1 antibody test result and the date
of first documented confirmed positive antibody test result,
provided that the time interval between the 2 tests was !3 years.
For the purpose of analysis, Western Europe was defined to
include those countries with a long history of good access to
antiretroviral drugs, as follows: Austria, Belgium, Cyprus, Ger-
many, Denmark, Spain, Finland, Greece, Ireland, Italy, Lux-
embourg, the Netherlands, Norway, Portugal, Sweden, France,
the United Kingdom, Switzerland, and Iceland. In our study,
Israel was also included in the Western Europe category.
Univariate and multivariate analyses were used to determine
predictors of TDR. All statistically significant ( ) univar-P ! .05
iate predictors of TDR that were not equally distributed over
time were considered as possible confounding factors in the
multivariate time trend analysis. The HIV-1 subtypes were de-
termined by use of the Rega HIV-1 subtyping tool (version 2.0,
available at http://www.bioafrica.net/subtypetool/html/) [4].
The data were analyzed using the statistical software R (version
2.3.1). Prevalence values were calculated with a 95% Wilson
score confidence interval (CI) on the basis of a binomial dis-
tribution. Categorical data were compared by use of the x2 test,
Fisher’s exact test, or logistic regression techniques. Continuous
data were investigated by means of Student’s t test, the Mann-
Whitney U test, linear regression, or Poisson regression. Phy-
logenetic analysis was performed to investigate whether some
samples belonged to tight clusters (potentially naive transmis-
sion clusters).
Results. In total, 2793 patients with newly diagnosed HIV-
1 infection met the predefined inclusion criteria: they were HIV-
1 drug naive, were 18 years old, provided a sample for ge-
notypic analysis within 6 months after diagnosis, and had viral
loads 11000 copies/mL. Sequence analysis was successful for
196% (2687) of 2793 patient samples. The baseline character-
istics of the patients are summarized in Table 1. The majority
of the Western European patients (964 [60%] of 1607) were
men who have sex with men (MSM), whereas almost all (316
[98%] of 323) of the patients originating from sub-Saharan
Africa were infected through heterosexual contact. Most of the
patients (1878 [70%] of 2687) had an unknown duration of
infection. A relatively high proportion of the study patients
(1175 [69%] of 1697) reported that the source of infection was
unknown. This was significantly more often the case among
MSM than among heterosexual patients (541 [44%] of 1230
vs 181 [18%] of 1004, respectively). Among all patients who
were infected through sexual contact, 4% (89 of 2234) knew
at the time of infection that the source was HIV positive. Most
of these patients (66 [73%] of 89) were MSM.
The prevalence of TDR was 8.4% from 2002 through 2006
(225 of 2687 patients; 95% CI, 7.4%–9.5%). The prevalence of
mutations associated with transmitted nucleoside reverse-tran-
scriptase inhibitor (NRTI) resistance was 4.7% (125 of 2687
patients; 95% CI, 3.9%–5.5%), that with transmitted nonu-
cleoside reverse-transcriptase inhibitor (NNRTI) resistance was
2.3% (62 of 2687 patients; 95% CI, 1.8%–2.9%), and that with
transmitted protease inhibitor (PI) resistance was 2.9% (79 of
2687 patients; 95% CI, 2.4%–3.6%). Dual class resistance oc-
curred in 17 cases (0.63%), and triple class resistance occurred
in 12 cases (0.45%). The most prevalent amino acid change
was RT215Y/F or RT215 revertant (67 [2.51%] of 225 patients).
RT41L was detected in 41 cases (1.51%). Other frequent (found
in 10.5% of cases) mutations were RT103N/S (1.42%), PR46I/
L (1.17%), RT219Q/E/R/N (0.84%), PR90M (0.67%), PR82A/
F/T/S (0.59%), RT210W (0.50%), and RT181C/I/V (0.50%).
Logistic regression showed no time trend (2002–2006) in the
overall TDR (odds ratio [OR], 0.89 [95% CI, 0.75–1.05];
) or in transmitted NRTI resistance (OR, 0.84 [95% CI,P p .17
0.67–1.04]; ) (Figure 1). Transmitted NNRTI resistanceP p .11
showed a statistically significant parabolic time trend with a
peak at the end of 2004 ( ). Finally, there was a statis-P p .02
tically significant decrease over time in transmitted PI resistance
(OR, 0.75 [95% CI, 0.57–0.99]; ) that coincided withP p .04
a statistically significant decrease in PR90M (OR, 0.39 [95%
CI, 0.20–0.76]; ).P p .006
All potential predictors of TDR were first tested univariately
(Table 1). Infection with subtype B virus and MSM transmission
route were statistically significantly ( ) associated withP ! .05
TDR. Being infected with a subtype B virus was the only inde-
pendent predictor in the multivariate approach. RT215Y/F re-
vertant and RT41L were significantly more prevalent in subtype
B compared to non-B (OR, 4.82 [95% CI, 2.31–11.64]; P !
; and OR, 3.10 [95% CI, 1.19–10.28]; ; respectively)..001 P p .01
Approximately two-thirds of the patients harbored a subtype
B virus (1795 [66.8%] of 2687). Subtype A was identified in
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Table 1. Comparison of Characteristics between Patients Infected with Human Immunodeficiency Virus Type 1 (HIV-1)
Harboring Transmitted Drug Resistance and Patients Infected with Wild-Type Virus
Univariate Multivariate
Characteristic Total TDR Wild type OR (95% CI) P OR (95% CI) P
Patients 2687 225 (8.4) 2462 (91.6)
Age, mean years  SD 36.7  10.8 36  10.7 37  10.8 0.93 (0.82–1.06) .3
Sex
Male 2080 (78) 183 (81) 1897 (77) 1.28 (0.90–1.86) .18
Female 598 (22) 42 (19) 556 (23)
Area of origin
Western Europe 1607 (60) 143 (64) 1464 (59) 1.19 (0.89–1.60) .26
Sub-Saharan Africa 323 (12) 23 (10) 300 (12)
Eastern Europe and Central Asia 424 (16) 37 (17) 387 (16)
Other 333 (12) 22 (9) 311 (13)
Route of transmission
MSM 1230 (46) 124 (55) 1106 (45) 1.50 (1.13–2.00) .004a 1.30 (0.94–1.80) .12
Heterosexual contact 1004 (37) 70 (31) 934 (38)
Injection drug use 208 (8) 8 (4) 200 (8)
Other 245 (9) 23 (10) 222 (9)
Area of infection
Western Europe and United States 1508 (56) 136 (60) 1372 (56) 1.21 (0.91–1.62) .18
Other 1179 (44) 89 (40) 1090 (44)
Duration of infection
!1 year 733 (27) 74 (33) 659 (27) 1.59 (0.62–5.22) .42
1–2 years 76 (3) 5 (2) 71 (3)
Unknown duration 1878 (70) 146 (65) 1732 (70)
CDC stage
A and B 2180 (87) 186 (87) 1995 (87) 0.93 (0.59–1.43) .83
C 338 (13) 27 (13) 311 (13)
Coinfection with hepatitis B virus 109 (4) 13 (6) 96 (4) 1.65 (0.83–3.03) .10
Coinfection with hepatitis C virus 242 (9) 14 (6) 228 (9) 0.66 (0.35–1.17) .17
STD within previous 2 years 432 (16) 48 (21) 384 (16) 1.40 (0.97–2.00) .07
Awareness of source of infection
Aware 522 (31) 37 (25) 485 (31) 1.38 (0.93–2.09) .11
Unaware 1175 (69) 112 (75) 1063 (69)
CD4 cell count, median cells/mm3 (IQR) 343 (370) 390 (380) 340 (368) 1.03 (0.98–1.09) .20
HIV-1 RNA, mean log copies/mL  SD 4.82  0.8 4.79  0.8 4.82  0.8 0.93 (0.78–1.12) .46
Subtype B 1795 (67) 178 (77) 1599 (65) 1.64 (1.19–2.29) .002a 1.48 (1.22–2.15) .04a
Subtype non-B 892 (33) 53 (23) 856 (35)
NOTE. Data are no. (%) of patients, unless otherwise indicated. Characteristics describe patients from whom a baseline HIV-1 genotypic
analysis was available. CDC, Centers for Disease Control and Prevention; CI, confidence interval; IQR, interquartile range; MSM, men who have
sex with men; OR, odds ratio; SD, standard deviation; STD, sexually transmitted disease; TDR, transmitted drug resistance.
a Statistically significant results ( ).P ! .05
265 cases (9.9%). Other non-B subtypes or circulating recom-
binant forms (CRFs) were C (6.7%), CRF02_AG (5.1%), G
(4.2%), F (1.3%), and less frequently (!1%) CRF06_cpx, D,
H, and J. There were 110 sequences (4%) that could not be
classified because they did not cluster unambiguously with ref-
erence sequences of the subtyping tool. Being infected with a
subtype B strain was more common among MSM than it was
among patients in other transmission groups (OR, 9.2 [95%
CI, 7.4–11.4]; ). Furthermore, subtype B was statisticallyP ! .001
significantly more prevalent in people infected in Western Eu-
rope or the United States than it was among those infected
elsewhere (75% vs 54%; OR, 2.6 [95% CI, 2.2–3.0]; ).P ! .001
Discussion. To our knowledge, the SPREAD Programme is
the first prospective, representative surveillance program of
TDR, its predictors, and its trends. The representative data
provide evidence of a stabilizing trend over time (2002–2006)
in the overall transmitted resistance in Europe. This study con-
firms that over the entire surveillance period, ∼1 in 10 patients
with newly diagnosed HIV-1 infection in Europe was infected
with a drug-resistant strain, as previous reports have already
indicated (SPREAD [2], EuroSIDA [5], and Combined Analy-
sis of Resistance Transmission over Time of Chronically and
Acutely Infected HIV Patients [CATCH] [6]).
Furthermore, we noticed a significant decrease over time in
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Figure 1. Time trends of transmitted drug resistance among patients
with newly diagnosed human immunodeficiency virus type 1 (HIV-1) in-
fection in Europe. NNRTI, nonucleoside reverse-transcriptase inhibitor;
NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor. 2/
2002, July–December 2002; 1/2003, January–June 2003; 2/2003, July–
December 2003; etc.
the prevalence of transmitted PI resistance and a significant
up-and-down trend in NNRTI resistance, the latter with a max-
imum prevalence at the end of 2004. This peak could not be
explained by the presence of transmission clusters of NNRTI
resistance in the middle of the sampling period (phylogenetic
analysis results available upon request). In addition, transmitted
NRTI resistance showed a decreasing trend; however, this was
not statistically significant. It should be stressed that this study
population consisted of patients with new diagnoses, the ma-
jority of whom (1878 [70%] of 2687) had an unknown duration
of infection. When the analysis was repeated on a subset (733
[27%] of 2687) of recently infected patients (duration of in-
fection, !1 year), statistically significant time trends were ob-
tained (eg, for PI resistance, ).P p .01
Of all the statistically significant univariate predictors of
TDR, only the proportion of patients infected in Western Eu-
rope or the United States statistically significantly decreased
over time ( ), which suggested that the increasing num-P ! .001
ber of immigrants in Europe with new diagnoses may be a con-
tributing factor to the decreasing trends of TDR. However, when
we corrected for this possible confounding factor, the signifi-
cance of the trends decreased only marginally, which suggested
that the increase in immigrants only slightly affected these
trends. We propose a more likely explanation for these trends:
on the one hand, resistance is decreasing in the treated pop-
ulation, and therefore the pool from which resistance is trans-
mitted is decreasing, whereas on the other hand, there are fewer
patients in whom treatment fails, so the sources of potential
transmission are shifting toward untreated patients. Indeed,
several published studies have reported a decreasing trend of
resistance among patients in whom treatment fails, and more
strikingly, one study also reported a parabolic trend in NNRTI
resistance (first increasing and subsequently decreasing) [7–12].
Thus, even though caution is needed when comparing preva-
lence rates between different studies, the trends in TDR (es-
pecially for NNRTI and PI) in this study seem to reflect the
decreasing trends in prevalence of resistance in the population
of patients who experienced treatment failure [7–12]. This con-
cordance is reassuring and indicates that our observed time
trends in TDR are a genuine consequence of improved clinical
care of treated patients rather than a methodological artifact.
We have to note here that some studies have reported increasing
prevalence of resistance over time, but we also note that these
studies were performed before or soon after highly active an-
tiretroviral therapy was introduced, during which time resis-
tance could accumulate in treatment-experienced patients and
subsequently be transmitted to newly infected patients.
In addition, we were able to investigate in a prospective
manner the factors associated with the risk for transmission of
drug-resistant HIV-1. Our results, consistent with previous re-
ports [5, 13], show that MSM infected with a subtype B virus
were more likely than other patients ( ) to be infectedP ! .01
with drug-resistant HIV-1. The most likely explanation for this
trend is the long history of antiretroviral drug use in Western
Europe and the United States, especially among MSM and pa-
tients infected with subtype B virus. In the multivariate analy-
sis, only subtype B proved to be independently associated with
TDR ( ). This could mean that we are seeing, not a ma-P p .04
jor import of resistant non-B strains into Europe, but rather a
local spread of resistant B strains within Europe. Future phy-
logenetic studies might give support to this hypothesis. How-
ever, it is also possible that this trend is (partially) attributable
to the fact that only for subtype B was there sufficient genuine
data to achieve statistical significance. The data on route of
transmission, country of infection, and awareness of the source
were available only if they were reported in the questionnaire;
this may introduce bias. For example, there may be a bias in
the patients’ declaration regarding sexual behavior (heterosex-
ual contact vs MSM), which could partially contribute to the
statistically significant association of subtype B with TDR ir-
respective of the transmission group.
In the absence of drug selective pressure, viruses with resis-
tance mutations have a tendency to revert to wild type because
of lower fitness of the virus carrying resistance mutations [14].
However, in chronically infected, drug-naive patients, these
originally transmitted resistance mutations can persist as minor
variants below the sensitivity of the genotypic assays [15]. The
fact that the mutations observed are not representative of the
mutations generally seen in the population with treatment fail-
ure might be the result of the reversion phenomenon (see also
the previous report from the SPREAD Programme [2]). Thus,
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we likely underestimate the calculated prevalence of transmit-
ted resistance. In addition, for patients who show any sign of
transmitted resistance, it may be advisable to use antiretrovi-
ral drug combinations with a “high genetic barrier,” because
additional mutations might have been transmitted that sub-
sequently reverted.
In conclusion, the prevalence of overall transmitted re-
sistance among patients in Europe in whom HIV-1 infection
was newly diagnosed was found to be stabilizing under 10%.
Concomitantly, transmitted NRTI resistance also seems to be
stabilizing, whereas transmitted NNRTI and PI resistance de-
creased over time. Subtype B infection was the strongest pre-
dictor of transmission of resistance.
GenBank accession numbers. The following are the
GenBank accession numbers for all of the sequences used in
this analysis: AJ971091, AJ971093, AJ971096, AJ971102,
AJ971103, AJ971106, AJ971107, AJ971109, AJ971110,
AJ971113, AJ971114, AJ971117, AJ971122, AJ971128,
AJ971133, AJ971140, AJ971143, AJ971144, AJ971268,
AJ971271, AJ971274, AJ971276–AJ971281, AJ971283,
AJ971285–AJ971287, AJ971289, AM113750, AY694290,
AY694313, AY694317, AY694318, AY694321, AY694322,
AY694324, AY694328–AY694330, AY694338, AY694339,
AY694343–AY694345, AY694350, AY694353, AY694361,






























AY940269, DQ974841, DQ974844, DQ974845, DQ974847,
DQ974848, DQ974850, DQ974853, DQ974854, DQ974857,
DQ974858, DQ974863–DQ974865, DQ974867–DQ974873,
DQ974875–DQ974877, DQ974880–DQ974882, DQ974887,
DQ974890, DQ974892, DQ974893, DQ974895–DQ974897,
DQ974899, DQ974902–DQ974906, DQ974908, DQ974910–
DQ974912, DQ974922–DQ974924, DQ974927–DQ974929,
DQ974931, DQ974932, DQ974941, DQ974944–DQ974947,
DQ974951–DQ974953, DQ974955DQ974963, DQ974965,
DQ974966, DQ974968, DQ974982–DQ974991, DQ974996–
DQ974998, DQ975003, DQ975011–DQ975015, DQ975018–
DQ975021, DQ975024, DQ975032, DQ975034–DQ975036,
DQ975044, DQ975136, DQ975139, DQ975140–DQ975147,
DQ975156–DQ975159, DQ975161–DQ975163, DQ975165,
DQ975169, DQ975172, DQ975173, DQ975187, EU248291–
EU248297, EU248299, EU248300, EU248302, EU248303,
EU248305–EU248307, EU248309, EU248310, EU248312,
EU248314, EU248315, EU248317, EU248320–EU248323,
EU248325, EU248327, EU248329, EU248331–EU248337,
EU248340, EU248341, EU248343–EU248345, EU248347–
EU248360, EU248363–EU248365, EU248368, EU248371–
EU248373, EU248376–EU248378, EU248382, EU248383,
EU248385–EU248387, EU248389, EU248392, EU248393,
EU248396, EU248399, EU248400, EU248401, EU248403,
EU248404, EU248406–EU248408, EU248410–EU248412,
EU248415–EU248419, EU248421–EU248426, EU248428,
EU248431, EU248432, EU248435, EU248439, EU248440–
EU248444, EU248446, EU248448, EU248449, EU248451,
EU248453, EU248455–EU248457, EU248459–EU248461,
EU248463–EU248466, EU248468–EU248474, EU248476,
EU248477, EU248479, EU248480, EU248483, EU248485,
EU248487–EU248490, EU248492, EU248494–EU248498,
EU248500–EU248505, EU248507, EU248509, EU248512,
EU248515, EU248517–EU248521, EU248523, EU248526–
EU248569, EU248571–EU248582, EU248584–EU248588,
EU673374–EU673397, FJ030767, FJ030769, FJ030771,
FJ030772, FJ185113–FJ185120, FJ185122, FJ185124,
FJ185125, FJ185127, and GQ398826–GQ401023.
SPREAD Programme investigators. Austria: E. Puchham-
mer-Stockl (national coordinator), M. Sarcletti, B. Schmied, M.
Geit, and G. Balluch. Belgium: A.-M. Vandamme (national co-
ordinator), J. Vercauteren, I. Derdelinckx, A. Sasse, M. Bogaert,
H. Ceunen, A. De Roo, S. De Wit, K. Deforche, F. Echahidi,
K. Fransen, J.-C. Goffard, P. Goubau, E. Goudeseune, J.-C.
Yombi, P. Lacor, C. Liesnard, M. Moutschen, D. Pierard, R.
Rens, Y. Schrooten, D. Vaira, A. Van den Heuvel, B. Van Der
Gucht, M. Van Ranst, E. Van Wijngaerden, B. Vandercam, M.
Vekemans, C. Verhofstede, N. Clumeck, and K. Van Laethem.
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Cyprus: L. Kostrikis (national coordinator), I. Demetriades, I.
Kousiappa, V. Demetriou, and J. Hezka. Czech Republic: M.
Bruckova (national coordinator), M. Linka, and L. Machala.
Denmark: C. Nielsen (national coordinator), L. B. Jørgensen,
J. Gerstoft, L. Mathiesen, C. Pedersen, H. Nielsen, A. Laursen,
and B. Kvinesdal. Finland: M. Salminen (national coordinator),
M. Ristola, K. Liitsola, J. Suni, and J. Sutinen. Germany: K.
Korn (national coordinator), C. Kücherer, T. Berg, P. Braun,
G. Poggensee, M. Däumer, J. Eberle, O. Hamouda, H. Heiken,
R. Kaiser, H. Knechten, H. Müller, S. Neifer, B. Schmidt, H.
Walter, B. Gunsenheimer-Bartmeyer, and T. Harrer. Greece: A.
Hatzakis (national coordinator), D. Paraskevis, E. Magiorkinis,
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